Along with Nutley-based Eisai, several other New Jersey-based giants in the space have conducted layoffs over the past few ...

SciClone will develop and distribute Tasfygo in greater China but Eisai will retain worldwide rights outside the region.

The European Commission had requested the committee consider new data on the drug that became available after it had adopted its positive opinion.

European Union's human medicines committee (CHMP) said on Friday it is not updating its opinion on Eisai and Biogen's ...

Eisai will maintain the rights to tasurgratinib worldwide outside of the licensed regions.

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi.

Eisai’s cuts will affect 121 employees across the Japanese company’s U.S. operations, including 57 people at its American ...

Eisai (ESAIY) and Biogen (BIIB) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has ...

Eisai (ESAIY) and Biogen (BIIB) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, ...

The European Union's drugs regulator said on Friday it concluded a review into the safety of Eisai and Biogen's Alzheimer's ...

Eisai plans to lay off 121 employees in the U.S. A former deputy director of China's drug agency is under investigation by ...

A new study has shown that two drugs - lecanemab and donanemab - could help patients stay independent by approximately 10–13 ...